Antibodies to gliadin detected by immunofluorescence and a micro-ELISA method: markers of active childhood and adult coeliac disease

U VOLTA, M LENZI, ROSANNA LAZZARI, F CASSANI, ANGELA COLLINA, F B BIANCHI, AND E PISI

From the Istituto di Patologia Medica I and Istituto di Clinica Pediatrica III, University of Bologna, Bologna, Italy

SUMMARY Antibodies to gliadin have been detected by immunofluorescence (IFL-AGA) and a micro-ELISA method (ELISA-AGA) in 45 out of 47 (96%) sera from patients with active childhood and adult coeliac disease. The two methods were more sensitive than R₁-reticulin antibodies (R₁-ARA) which were found only in 28 of the same patients (60%). R₁-ARA were always negative in the 26 sera from patients with childhood coeliac disease and adult coeliac disease after gluten free diet, while IFL- and ELISA-AGA were respectively found in three (12%) and in four (15%) out of these patients. Moreover, while R₁-ARA and IFL-AGA were strictly confined to coeliac disease, ELISA-AGA were occasionally found in patients with control diseases. These 'false positive' antibodies were all of IgG class and had low titres. In our experience IFL- and ELISA-AGA of IgA class were strictly confined to active childhood coeliac disease and adult coeliac disease. The detection of AGA is useful in monitoring the diet and in the follow up of coeliac disease. IFL- and ELISA-AGA, then, are to be preferred to R₁-ARA for the screening of coeliac patients.

Circulating antibodies to reticulin and gliadin have been described in sera from patients with childhood and adult coeliac disease.^{1,2}

R₁-reticulin antibodies (R₁-ARA), detected by immunofluorescence, have been detected in active childhood coeliac disease and adult coeliac disease with a prevalence varying from 36% to 78%.³⁻⁶ Because of the low sensitivity, R₁-ARA have proved of limited value in the diagnosis of gluten enteropathy. Their specificity, however, has been reported as high, although rare 'false positive' cases have been described in Crohn's disease and dermatitis herpetiformis.^{7,8}

Antibodies to gliadin, detected by immunofluorescence (IFL-AGA) and recently by a micro-ELISA method (ELISA-AGA), appear to be far more sensitive, though less specific, than R₁-ARA, being also found in 'control' gastroenterological disorders. In fact, IFL-AGA

were present in 100% of sera from 32 children with childhood coeliac disease on free diet or after gluten challenge⁹ and ELISA-AGA were found by Savilahti *et al*¹⁰ in all the 11 children (aged under 2 years) with untreated childhood coeliac disease. Antibodies to gliadin were also found in some cases of Crohn's disease, ulcerative colitis, cow's milk enteropathy, transient gluten intolerance and dermatitis herpetiformis.^{9,11,12}

R₁-ARA, IFL- and ELISA-AGA were confined to IgA and IgG class.^{1,2,5,10} Moreover, R₁-ARA and ELISA-AGA of IgA class were only present, with few exceptions, in patients with active coeliac disease.^{5,10}

The aim of this work was to define the relevance of R₁-ARA, IFL- and ELISA-AGA in the diagnosis of childhood coeliac disease and adult coeliac disease. Therefore, we have compared the immunofluorescence and the micro-ELISA methods, evaluating their sensitivity and specificity, to establish which of the three antibodies proved to be more useful for the screening of coeliac patients.

Address for correspondence: Dr Umberto Volta, Istituto di Patologia Medica I, Policlinico S Orsola, Via Massarenti 9, 40138 Bologna, Italy.

Received for publication 3 August 1984

Methods

PATIENTS

A total of 309 sera was studied. Fifty seven sera from patients with childhood coeliac disease (aged 2–10 years) and 16 sera with adult coeliac disease, at different stages of the disease, diagnosed according to defined criteria,¹³ were tested. They included 24 sera from patients with untreated and newly diagnosed childhood coeliac disease, 22 from patients after one year of gluten free diet and 11 from patients after two months of gluten challenge. Sera from adult coeliac disease patients came from 12 untreated cases and four after one year of gluten free diet. In all coeliac disease cases the diagnosis was based on the intestinal biopsy. In the 36 newly diagnosed patients subtotal villous atrophy was found in 34 and partial villous atrophy in two. All the 26 patients biopsied after one year of gluten free diet showed a normal villous morphology, while 10 of the 11 patients studied after two months of gluten challenge displayed a subtotal villous atrophy and one a partial villous atrophy.

As control diseases, sera from 191 patients with various intestinal and non-intestinal pathological conditions associated with immunological abnormalities were tested. They included sera from 40 children (15 with postenteritis syndrome and 25 with IgA deficiency) and from 151 adults (31 with ulcerative colitis, 15 with Crohn's disease, 55 with primary biliary cirrhosis and autoimmune chronic hepatitis and 50 with rheumatoid arthritis). Patients with intestinal involvement had a peroral biopsy which excluded villous abnormalities. Thirty sera from healthy children and 15 from blood donors, sex and age matched with childhood coeliac disease and adult coeliac disease patients respectively, were also studied.

R₁-ARA

Diluted (1:10) sera were tested by immunofluorescence using a fluorescein isothiocyanate conjugated sheep antihuman F(ab)₂ serum (Wellcome) on 5 μ cryostat sections of rat liver, kidney, and stomach.¹⁴ Positive sera were also tested on human liver sections, surgically taken from blood O group patients who underwent operation for gall bladder stones. Monospecific rabbit anti-human fluorescein isothiocyanate conjugated IgG, IgA and IgM sera (Behringwerke) were used to assess the Ig class of the antibodies. Positive sera were titred to end-point by immunofluorescence. Slides were read under a Leitz microscope with vertical illumination (Xenon XBO 75W lamp).

IFL-AGA

Antibodies to gliadin were detected by a modification of the immunofluorescence method described for R₁-ARA.^{9 15} Cryostat sections were pretreated with an aqueous solution of crude gliadin (Sigma) (0.1 mg/ml) for 30 minutes. After washing in phosphate buffered saline to remove unbound wheat protein, gliadin treated sections were processed as for R₁-ARA.

ELISA-AGA

The micro-ELISA test used in this study was modified from that described by Lenzi *et al.*¹⁶ Briefly, the standard coating conditions were as follows: 200 μ l of crude gliadin (Sigma) at the concentration of 0.1 mg/ml in 0.005 M carbonate buffer, pH 9.6, were seeded in each well of microplates (Dynatech 129) and incubated overnight at 4°C. Wells were then washed three times with phosphate buffered saline containing 0.5% Tween 20. Two hundred microlitres of patients' serum, previously diluted with phosphate buffered saline (1:500 and 1:100 respectively for the detection of IgG and IgA antibodies), were added to each gliadin-coated well. Incubation was carried out for three hours at room temperature. After three washings, 200 μ l of alkaline phosphatase conjugated rabbit anti-human IgG (raised, isolated by affinity chromatography using commercially available IgG – Miles – as antigen and conjugated with alkaline phosphatase – Sigma – in our laboratory) and alkaline phosphatase-conjugated rabbit anti-human IgA (Sigma) were added to each well and left at room temperature for three hours. Alkaline phosphatase activity bound to the wells was then measured by adding 200 μ l of fresh substrate solution (P-nitrophenyl disodium phosphate) in diethanolamine buffer pH 9.8. After incubation at room temperature for 30 minutes the reaction was stopped by adding 50 μ l of 3M NaOH and absorbance was measured by a Dynatech micro-ELISA autoreader MR 580. In these experiments optimal gliadin concentration and serum dilution were used according to previously determined titration curves, showing that optimal optical density values were obtained with concentrations and dilutions used.

Results

Results are reported in the Table.

R₁-ARA were detected in only 12 (50%) of the 24 children with untreated childhood coeliac disease. These antibodies were also found in seven (64%) of the 11 children with childhood coeliac

Table Prevalence of R₁-ARA, IFL- and ELISA-AGA in the 309 sera tested

	No	IFL-AGA			ELISA-AGA			R ₁ -ARA		
		IgA (%)	IgG (%)	Total (%)	IgA (%)	IgG (%)	Total (%)	IgA (%)	IgG (%)	Total (%)
<i>Childhood coeliac disease (CCD)</i>										
newly diagnosed, untreated	24	71	54	100	79	100	100	29	21	50
confirmed after gluten challenge	11	64	36	91	63	82	91	36	27	64
after 1 year on gluten free diet	22	—	14	14	5	18	18	—	—	—
<i>Adult coeliac disease (ACD)</i>										
newly diagnosed, untreated	12	58	33	92	58	92	92	42	33	75
after 1 year on gluten free diet	4	—	—	—	—	50	50	—	—	—
<i>Disease controls</i>										
Postenteritis syndrome	15	—	—	—	—	20	20	—	—	—
IgA deficiency	25	—	—	—	—	4	4	—	—	—
Ulcerative colitis	31	—	—	—	—	10	10	—	—	—
Crohn's disease	15	—	—	—	—	13	13	—	—	—
Primary biliary cirrhosis and autoimmune chronic hepatitis	55	—	—	—	—	—	—	—	—	—
Rheumatoid arthritis	50	—	—	—	—	—	—	—	—	—
<i>All disease control cases</i>	191	—	—	—	—	5	5	—	—	—
<i>All healthy control cases</i>	45	—	—	—	—	—	—	—	—	—

disease after gluten challenge and were never observed in the 22 with childhood coeliac disease after gluten free diet. Of the 12 patients with untreated adult coeliac disease, nine (75%) were positive for R₁-ARA, while the four with adult coeliac disease after gluten free diet were negative. None of the 191 control disease patients, as well as the 45 healthy controls, turned out to be positive. R₁-ARA titres varied from 1:20 to 1:320 with a slight prevalence of IgA antibodies.

IFL-AGA were found in 100% children with untreated childhood coeliac disease, in 91% cases after gluten challenge and in three (14%) cases after gluten free diet. IFL-AGA were detected in 11 (92%) patients with untreated adult coeliac disease: none of the four adult coeliac disease patients after gluten free diet was positive. All the 191 sera from control disease patients and the 45 from healthy controls were negative. IFL-AGA showed the same immunofluorescence pattern of R₁-ARA. Though their titres were slightly higher (ranging from 1:20 to 1:640) no significant difference with R₁-ARA titres was shown. Moreover, IFL-AGA were more frequently confined to the IgA class (66%).

ELISA-AGA were detected in 100% untreated childhood coeliac disease and in 91% childhood coeliac disease after gluten challenge. They were also present in four (18%) cases of childhood coeliac disease after gluten free diet and in all these patients the antibodies were of IgG class, associated to IgA in one case only. ELISA-AGA were observed in 11 (92%) of the 12 untreated

adult coeliac disease and also two of the four cases after gluten free diet were positive. In control disease groups ELISA-AGA were found in three (20%) of the 15 sera from patients with postenteritis syndrome, in two (13%) of the 15 with Crohn's disease, in three (10%) of the 31 with ulcerative colitis and in one (4%) of the 25 with IgA deficiency. These antibodies were always confined to IgG class. The results of the healthy controls were negative. The ELISA-AGA titres turned out to be far higher in the sera from untreated coeliac patients and among these in childhood coeliac disease than in adult coeliac disease subjects (Figure).

The statistical analysis (χ^2 , Yates' correction) showed a significant difference between IFL-/ELISA-AGA and R₁-ARA in childhood coeliac disease ($p < 0.005$), and IgG ELISA-AGA and IgG IFL-AGA both in childhood coeliac disease ($p < 0.005$) and in adult coeliac disease ($p < 0.05$).

As most patients with active coeliac disease (both newly diagnosed and after gluten challenge) had the highest histological degree of mucosal damage, no attempt was made to correlate histological results and titres of the various antibodies tested. The three cases with partial villous atrophy had low titre antibodies, both in immunofluorescence and ELISA.

Discussion

Both IFL- and ELISA-AGA turned out to be more

sensitive than R₁-ARA in diagnosing childhood coeliac disease and adult coeliac disease. R₁-ARA were, however, strictly confined to childhood coeliac disease and adult coeliac disease, as did IFL-AGA, while ELISA-AGA were occasionally found in disease control patients. R₁-ARA and IFL-AGA showed the same reticulin pattern and, when the two antibodies were present in the same serum, antibodies to gliadin titre was higher than R₁-ARA titre.

IFL- and ELISA-AGA showed a very similar sensitivity, while IFL-AGA were slightly more specific than ELISA-AGA. Unlike Unsworth *et al*^{9,11} we could not find IFL-AGA in groups other than childhood coeliac disease and adult coeliac disease. The low prevalences of IFL- and ELISA-AGA and R₁-ARA in the gluten free diet subgroup are probably because our patients were

tested after a longer period of gluten free diet (one year instead of three months, as in other works).^{1,9} Both sensitivity and specificity of IgA and IgG antibodies were similar for IFL-AGA, while IgG ELISA-AGA were more sensitive than IgG IFL-AGA both in childhood coeliac disease and in adult coeliac disease.

In our experience IgA AGA, detected both by ELISA and immunofluorescence, were strictly confined to active coeliac disease, as all the 'false positive' antibodies to gliadin, shown by ELISA method, were of IgG class. It is also interesting to remark that these 'false positives' were less than 5% in control disease groups and that their titre was very low (Figure).

The presence of antibodies to gliadin, especially of IgA class, warrants a jejunal biopsy in children and adults with suspected coeliac disease even if

Figure ELISA titres of serum antibodies to gliadin (ELISA-AGA) unl (upper normal limit) = $x + 3$ SD of controls.

A = untreated childhood coeliac disease (CCD).

B = CCD after gluten challenge.

C = CCD on gluten free diet.

D = .004 untreated adult coeliac disease (ACD).

E = ACD on gluten free diet.

F = postenteritis syndrome.

G = IgA deficiency.

H = ulcerative colitis.

I = Crohn's disease.

L = primary biliary cirrhosis and autoimmune chronic hepatitis.

M = rheumatoid arthritis.

N = healthy controls.

other parameters are negative. Moreover, as a positive antibodies to gliadin test is closely related to the active phases of childhood coeliac disease and adult coeliac disease, their research can be useful both to evaluate the effect of gluten free diet and to establish when a new biopsy is appropriate after gluten challenge.

On the whole, IFL- and ELISA-AGA should be preferred to R₁-ARA for the screening of coeliac patients; the two tests give similar results and the choice of one of the two depends on the facilities available in each laboratory.

References

- 1 Unsworth DJ, Kieffer M, Holborow EJ, Coombs RRA, Walker-Smith JA. IgA anti-gliadin antibodies in coeliac disease. *Clin Exp Immunol* 1981; **46**: 286-93.
- 2 Eterman KP, Feltkamp TEW. Antibodies to gluten and reticulin in gastrointestinal diseases. *Clin Exp Immunol* 1978; **31**: 92-9.
- 3 Seah PP, Fry L, Holborow EJ *et al.* Antireticulin antibody: incidence and diagnostic significance. *Gut* 1973; **14**: 311-5.
- 4 Mallas EG, Williamson N, Cooper BT, Cooke, WT. IgA class reticulin antibodies in relatives of patients with coeliac disease. *Gut* 1977; **18**: 647-50.
- 5 Eade OE, Lloyd RS, Lang C, Wright R. IgA and IgG reticulin antibodies in coeliac and non-coeliac patients. *Gut* 1977; **18**: 991-3.
- 6 Lazzari R, Volta U, Masi M *et al.* R₁ antireticulin antibody: probable marker of childhood coeliac disease on a normal diet and on gluten challenge. *Ital J Gastroenterol* 1982; **14**: 59.
- 7 Alp MH, Wright R. Autoantibodies to reticulin in patients with idiopathic steatorrhoea, coeliac disease and Crohn's disease, and their relation to immunoglobulins and dietary antibodies. *Lancet* 1971; **25**: 682-5.
- 8 Lancaster-Smith M, Kumar P, Clark ML, Marks R, Johnson GD. Antireticulin antibodies in dermatitis herpetiformis and adult coeliac disease. *Br J Dermatol* 1975; **92**: 37-42.
- 9 Unsworth DJ, Manuel PD, Walker-Smith JA, Campbell CA, Johnson GD, Holborow EJ. New immunofluorescent blood test for gluten sensitivity. *Arch Dis Child* 1981; **56**: 864-8.
- 10 Savilahti E, Perkkio M, Kalimo K, Viander M, Vainio E, Reunala T. IgA antigliadin antibodies: a marker of mucosal damage in childhood coeliac disease. *Lancet* 1983; **12**: 320-2.
- 11 Unsworth DJ, Walker-Smith JA, Holborow EJ. Gliadin and reticulin antibodies in childhood coeliac disease. *Lancet* 1983; **16**: 874-5.
- 12 Huff JC, Weston WL, Zirker DK. Wheat protein antibodies in dermatitis herpetiformis. *J Invest Dermatol* 1979; **73**: 570-4.
- 13 Anonymous. Confirming the diagnosis of coeliac disease [Editorial]. *Br Med J* 1975; **4**: 2.
- 14 Rizzetto M, Doniach D. Types of 'reticulin' antibodies detected in human sera by immunofluorescence. *J Clin Pathol* 1973; **26**: 841-51.
- 15 Unsworth DJ, Johnson GD, Haffenden G, Fry L, Holborow EJ. Binding of wheat gliadin in vitro to reticulin in normal and dermatitis herpetiformis skin. *J Invest Dermatol* 1981; **76**: 88-93.
- 16 Lenzi M, Cassani F, Bianchi FB, Franceschi C. A micro-ELISA assay to detect anti-liver-specific protein antibodies in the sera of patients with liver diseases. *J Immunol Methods* 1983; **57**: 59-69.